Contact Person
    Nicole Mastrell

    Event Manager & PA to CEO
    Phone: (M) +45 6141 8634

    Good Morning Meeting – Biomarkers analysis challenges in Clinical Trials

    Welcome to MVA’s Good Morning Meeting on “Biomarkers analysis challenges in Clinical Trials” with HalioDx.

    One of the biggest challenges in immunotherapy area is to find accurately which patients will benefit from a therapy or a combination of therapies. To help drug developers getting this information, the assessment of biomarkers through clinical research studies represent a key step.

    Date: Tuesday June 18th 2019
    Time: 8:30 – 11:00
    Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Danmark – Ground floor



    8:30 – 9:00

    Registration & Coffee

    9:00 – 9:15

    Aurélie Fugon, Associate Director BD, HalioDx

    9:15 – 9:45

    Evaluation of immune responses in clinical phase I/II trials in tumors treated with the oncolytic peptide LTX-315
    Vibeke Sundvold Gjerstad, Translational Scientist, Lytix Biopharma

    9:45 – 10:15

    Immunogram proof of concept
    Jacques Fieschi, PhD, Senior Director R&D, HalioDx

    10:15 – 10:30

    Q&A session

    10:30 – 11:00



    Vibeke Sundvold Gjerstad
    Translational Scientist
    Lytix Biopharma
      Jacques Fieschi, PhD
    Senior Director R&D


    Arranged by:

    In collaboration with: